GILD - Gilead Sciences Shares Trade Higher After Bullish Analyst Upgrades Stock | Benzinga
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) are trading higher into Friday’s trading session after Bank of America Securities upgraded the stock, highlighting an underappreciated growth potential in its core HIV business and emerging hematology/oncology franchises.
Here’s what investors need to know.
The GILD Analyst: Geoff Meacham upgraded Gilead Sciences to a Buy rating from a Neutral rating, and raised the price target to $95 from $88.
The GILD Takeaways: The company is showing signs of a brighter future, with accelerating growth that is currently flying under the radar for many investors, Meacham said in a Friday note to investors. At the heart of underappreciation is the ...